|
|
Session 9: Innovative Metabolic Diseases Drug Discovery & Development
|
|
Session Chair: Dr. Gary J. Grover, Director of Pharmacology, Eurofins Scientific, Associate Professor of Physiology and Biophysics, Robert Wood Johnson Medical School, New Jersey, USA
Co-Chair: Dr. Subrata Chakrabarti, Professor, Department of Pathology, University of Western Ontario, Canada |
|
|
Title: RNA Interference for Target Identification and Validation
Dr. Ruojing Yang, Senior research biologist, Merck & Co. Metabolic diseases division
|
|
Title: Role of a Novel Nuclear Oxysterol in Lipid Metabolism, Potential Usage in the Therapy of Hyperlipidemia
Dr. Shunlin Ren, Associate Professor,McGuire Research Institute/Virginia Commonwealth University, USA
|
|
Title: Gastrin-releasing Peptide Receptor (GRPR) Signaling Pathway as a Potential Molecular Target for Cancer, Inflammatory and Neurological Disorders
Dr. G. Schwartsmann, Professor, Medicine Federal University Porto Alegre, Brazil
|
|
Title: The Role of Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) in Human Ovarian Regulation
Dr. Donna Seto-Young, Director of Endocrinology Research Laboratory, Associate Professor of Medicine, Albert Einstein College of Medicine, Beth Israel Medical Center, Division of Enocrinology & Metabolism, USA
|
|
Title: Gonadotropin-Inhibitory Hormone (GnIH): Discovery, Mode of Action, Functional, Significance and Prospective Application to Reproductive Dysfunction
Dr. Kazuyoshi Tsutsui, Professor, Laboratory of Integrative Brain Sciences, Department of Biology, Waseda University, Japan
|
|
Title: Effects of Insulin Resistance on Coronary In-stent Restenosis
Dr. Kazuaki Nishio, Showa University, Tokyo, Japan
|
|
Title: Understanding Endothelial Cell Signaling to Identify Potential Future Treatment Strategies for Vascular Diseases in Diabetes
Dr. Subrata Chakrabarti, Professor, Department of Pathology, University of Western Ontario, Canada
|
|
Title: Evaluating Current and Future Anti-obesity Pharmacotherapy in the Context of Historical Controversies
Dr. David W Haslam, Clinical Director, & immediate former Chair of National Obesity Forum., Chair of Foundations Charity,.UK
|
|
Title: The Endocannabinoid System: a Therapeutic Target for Reducing Obesity and Cardiometabolic Risk Factors?
Dr. Marie-Paule GONTHIER, Laboratoire de Biochimie et G¨¦n¨¦tique Mol¨¦culaire, Universit¨¦ de La R¨¦union, FRANCE s
|
|